Ujwala's mailing address filed with the SEC is C/O SUMMIT THERAPEUTICS INC., 2882 SAND HILL ROAD, SUITE 106, MENLO PARK, CA, 94025.
Over the last 4 years, insiders at Summit Therapeutics Inc have traded over $0 worth of Summit Therapeutics Inc stock and bought 529,946,601 units worth $632,334,967 . The most active insiders traders include Robert W Duggan, Mahkam Zanganeh, and Manmeet Singh Soni. On average, Summit Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of $751,966,329. The most recent stock trade was executed by Mahkam Zanganeh on 26 March 2024, trading 110,321 units of SMMT stock currently worth $411,497.
summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.
Summit Therapeutics Inc executives and other stock owners filed with the SEC include: